Viewed: 264
Emailed: 0
PDF Downloaded: 262
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 12, Issue : 2, Year : 2022
Article Page : 370-373
https://10.18231/j.pjms.2022.070
Abstract
Objectives: This study was conducted to studyprescribing pattern of drugs amongst mild to moderate COVID-19 patients in COVID dedicated medical college hospital in northern India.
Materials and Methods: A retrospective, descriptive study was conducted in a COVID dedicated medical college hospital at Uttar Pradesh India. Demographic data, hospitalization data, and drug utilization pattern of all laboratory confirmed mild to moderate COVID-19 patients of all age groups, either sex, and admitted between 01 July 20 to 30 September 2020 were retrieved and analyzed.
Results: Out of 767 COVID-19 patients 66.62% were male and 33.38% were female. Mean age of COVID-19 patients were 51 years. Average numbers of drug prescribed per patients were seven. Number of drug prescribed per patients increased in older COVID-19 patients and COVID-19 patients having co-morbidities. Most common prescribed drug was paracetamol (100%), followed by Vitamin C (99.08%), followed by multivitamins (97.78%), followed by protonpump inhibitors (74.84%), followed by antihistaminices in 51.89% cases followed by hydroxychloroquine and Ivermectin was prescribed in 47.84% cases. Most common antibiotic prescribed was Amoxicillin (40.94%), followed by Azithromycin (34.41%), and followed by Doxycycline (29.20%) cases. Flavipiravir was prescribed in 15.12% cases. Corticosteroids were prescribed in 16.30% cases.
Conclusion: Drug used for admitted COVID-19 patients were diverse and were in accordance to existing guidelines.
Keywords: COVID-19, Prescribing pattern of drugs
How to cite : Agrawal P, Singhal A, Agrawal V K, Prescribing pattern of drugs amongst COVID-19 patients in a medical college hospital. Panacea J Med Sci 2022;12(2):370-373
Copyright © 2022 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)